We are live on
!
Find out more
Harvard Bioscience
HBIO
HBIO
36 hedge funds and large institutions have $7.72M invested in Harvard Bioscience in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
918% more call options, than puts
Call options by funds: $112K | Put options by funds: $11K
31.54% more ownership
Funds ownership: 3.92% → 35.45% (+32%)
34% less capital invested
Capital invested by funds: $11.7M → $7.72M (-$3.95M)
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
43% less funds holding
Funds holding: 63 → 36 (-27)
90% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 29
Holders
36
Holders Change
-27
Holders Change %
-42.86%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
10
Reduced
17
Closed
29
Calls
$112K
Puts
$11K
Net Calls
+$101K
Net Calls Change
+$39K
Top Buyers
Top Sellers
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$274K |
| 2 |
Jane Street
New York
|
-$98.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$93.5K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$93.1K |
| 5 |
Citigroup
New York
|
-$73.3K |
